Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
Authors
Khoja, LeilaKumaran, Gireesh C
Zee, Ying-Kiat
Murukesh, Nishanth
Swindell, Ric
Saunders, Mark P
Clamp, Andrew R
Valle, Juan W
Wilson, Gregory
Jayson, Gordon C
Hasan, Jurjees
Affiliation
The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2013-10-22
Metadata
Show full item recordAbstract
The vascular endothelial growth factor pathway is strongly implicated in cancer-related angiogenesis. Antiangiogenic agents such as bevacizumab commonly cause hypertension (HTN) and proteinuria (PTN), which may be biomarkers of response and clinical outcome.Citation
Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. 2013: J Clin GastroenterolJournal
Journal of Clinical GastroenterologyDOI
10.1097/MCG.0b013e3182a8804cPubMed ID
24153157Type
ArticleLanguage
enISSN
1539-2031ae974a485f413a2113503eed53cd6c53
10.1097/MCG.0b013e3182a8804c
Scopus Count
Collections
Related articles
- Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
- Authors: Lombardi G, Zustovich F, Farina P, Fiduccia P, Della Puppa A, Polo V, Bertorelle R, Gardiman MP, Banzato A, Ciccarino P, Denaro L, Zagonel V
- Issue date: 2013 Jan
- The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
- Authors: Budai B, Nagy T, Láng I, Hitre E
- Issue date: 2013 Jan
- Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab.
- Authors: Uysal M, Bozcuk H, Sezgin Göksu S, Murat Tatli A, Arslan D, Gündüz S, Senol Coskun H, Ozdogan M, Savas B
- Issue date: 2014 May
- Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
- Authors: Akun E, Okutur K, Seber S, Korkmaz T, Aydin K, Bozkurt M, Namal E, Hasbal B, Tecimer C, Demir G
- Issue date: 2012 Oct-Dec
- Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer.
- Authors: Iwasa S, Nakajima TE, Nagashima K, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y
- Issue date: 2013 Jan